Comprehensive structure-activity-relationship of azaindoles as highly potent FLT3 inhibitors |
| |
Authors: | Sebastian H Grimm Berend Gagestein Jordi F Keijzer Nora Liu Ruud H Wijdeven Eelke B Lenselink Adriaan W Tuin Adrianus MCH van den Nieuwendijk Gerard JP van Westen Constant AA van Boeckel Herman S Overkleeft Jacques Neefjes Mario van der Stelt |
| |
Institution: | 1. Department of Molecular Physiology, Leiden Institute of Chemistry, Leiden University, Leiden, the Netherlands;2. Oncode Institute and Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands;3. Computational Drug Discovery, Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands;4. Department of Bio-Organic Synthesis, Leiden Institute of Chemistry, Leiden University, Leiden, the Netherlands;5. Pivot Park Screening Center, Oss, the Netherlands |
| |
Abstract: | Acute myeloid leukemia (AML) is characterized by fast progression and low survival rates, in which Fms-like tyrosine kinase 3 (FLT3) receptor mutations have been identified as a driver mutation in cancer progression in a subgroup of AML patients. Clinical trials have shown emergence of drug resistant mutants, emphasizing the ongoing need for new chemical matter to enable the treatment of this disease. Here, we present the discovery and topological structure-activity relationship (SAR) study of analogs of isoquinolinesulfonamide H-89, a well-known PKA inhibitor, as FLT3 inhibitors. Surprisingly, we found that the SAR was not consistent with the observed binding mode of H-89 in PKA. Matched molecular pair analysis resulted in the identification of highly active sub-nanomolar azaindoles as novel FLT3-inhibitors. Structure based modelling using the FLT3 crystal structure suggested an alternative, flipped binding orientation of the new inhibitors. |
| |
Keywords: | H-89 analogs Fms-like tyrosine kinase 3 (FLT3) Acute myeloid leukemia (AML) Inhibitors |
本文献已被 ScienceDirect 等数据库收录! |
|